medigraphic.com

2016, Number 3

<< Back Next >>

Rev Med MD 2016; 7.8 (3)

Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)

Torres-Ruíz JJ, Martín-Nares E, López-Íñiguez A

Language: Spanish
References: 100
Page: 170-181
PDF size: 1187.79 Kb.


ABSTRACT

In 2011, Shoenfeld and Agmon-Levin coined the termed “Autoimmune/Inflammatory Syndrome Induced by Adjuvants” (ASIA) to describe the spectrum of immune-mediated conditions triggered by adjuvants. Such conditions appear with a variable latency period and occur as a result of the interplay of genetic and environmental factors. Five conditions have been included under the term ASIA: siliconosis, Gulf War syndrome, macrophage myofasciitis, sick building syndrome and post-vaccination phenomena. In addition, different biomaterials and metals are now considered as triggering factors of ASIA. The following review will describe the different conditions included in ASIA and the suspected mechanism of adjuvant-induced autoimmunity.


REFERENCES

  1. 1.Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33(4):492-503.

  2. 2.Ahmed SS, Schur PH, Macdonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 2014;50:1-11.

  3. 3.Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, Shoenfeld Y. Autoimmune (Auto-inflammatory) syndrome induced by adjuvants (ASIA) - Animal models as a proof of concept. Curr Med Chem 2013;20:4030-6.

  4. 4.Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus 2012;21:6.

  5. 5.Reeves Wh, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009;30(9):455-64.

  6. 6.van Der Laan JW, Gould S, Tanir JY, Vaccines Ilsi Hesi, Adjuvants Safety Project Committee. Safety of vaccine adjuvants: focus on autoimmunity. Vaccine 2015;33(13):1507-14.

  7. 7.Petrovsky N, Aguilar JC. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 2004;82:488-96.

  8. 8.Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol 2011;41(2):163-8.

  9. 9.Petrovsky N, Aguilar JC. Vaccine adjuvants: Current state and future trends. Immunology Cell Biology 2004;82:9.

  10. 10.Agmon-Levin N, Arango MT, Kivity S, et al. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun 2014;54:21-32.

  11. 11.Holmdahl R, Lorentzen JC, Lu S, Olofsson P, Wester L, Holmberg J, Pettersson U. Arthritis induced in rats with non- immunogenic adjuvants as models for rheumatoid arthritis. Immunological reviews 2001;184:19.

  12. 12 . Shoen feld Y, Agmon- Levin N. ASIA ' Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011;36(1):4-8.

  13. 13.Caldeira M, Caldeira Ferrerira A. Siliconosis: autoimmune/inflamatory syndrome inducedby adjuvants (ASIA). Isr Med Assoc J 2012;14(2):137-8.

  14. 14.Bizjak M, Selmi C, Praprotnik S, et al. Silicone implants and lymphoma: The role of inflammation. J Autoimmun 2015;65:64-73.

  15. 15.Perricone C, Colafrancesco S, Mazor RD, Soriano A , Agmon - Levin N , Shoen feld Y . Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun 2013;47:1-16.

  16. 16.Agmon-Levin N, Hughes GR, Shoenfeld Y. Thes pectrumo fASIA: ' Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus 2012;21(2):118-20.

  17. 17.Alijotas-Reig J, Garcia-Gimenez V, Llurba E, Vilardell-Tarrés M. Autoimmune/inflammatory syndrome (ASIA) induced by biomaterials injection otherthansiliconem grade. Lupus 2012;21(12):1326-34. 18.Cervera R. 'ASIA': a new systemic autoimmune syndrome? Lupus 2011;20(7):665-6.

  18. 19.Salemo S, D'Amelio R. Could autoimmunity be induced by vaccination?. Int Rev Immunol 2010;29:247-69.

  19. 20.Stratton Kr, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994;271(20):1602-5.

  20. 21.Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun 1996;9(6):699-703.

  21. 22.Ropper AH, Victor M. Influenza vaccination and the Guillain-Barré syndrome. NEnglJMed 1998;339(25):1845-6.

  22. 23.Tishler M, Shoenfeld Y. Vaccination may be associated with autoimmune diseases. Isr Med Assoc J 2004;6(7):430-2.

  23. 24.Agmon-Levin N, Shoenfeld Y. Chronic fatigue syndrome with autoantibodies--the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008;8(1):52-5.

  24. 25.Cerpa-Cruz S, Paredes-Casillas P, Landeros Navarro E, Bernard-Medina AG, Martinez-Bonilla G, Gutierrez-Urena S. Adverse events following immunization with vaccines containing adjuvants. Immunol Res 2013;56(2-3):299-303.

  25. 26.Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P et al. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld's syndrome). Lupus 2012;21(2):128-35.

  26. 27.Ramachandran G. Gram-positive and gramnegative bacterial toxins in sepsis: a brief review. Virulence 2014;5(1):213-8.

  27. 28.Boele LC, Bajramovic JJ, De Vries AM, Voskamp- Visser IA, Kaman WE, Van Der Kleij D. Activation of Toll-like receptors and dendritic cells by a broad range of bacterial molecules. Cell Immunol 2009;255(1-2):17-25.

  28. 29.Francis L, Perl A. Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumtol 2010;5(1):59-74.

  29. 30.Bekeredjian-Ding I, Greil J, Ammann S, Parcina M. Plasmacytoid Dendritic Cells: Neglected Regulators of the Immune Response to Staphylococcus aureus. Front Immunol 2014;5:238.

  30. 31.Elkon KB, Stone VV. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res 2011;31(11):803-12.

  31. 32.Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relations hipbet ween human sand their environment. Autoimmun Rev 2008;8(1):1-4.

  32. 33.Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol 2012;42(1):102-11.

  33. 34.Fourneau JM, Bach JM, van Endert PM, Bach JF. The elusive case for a role of mimicry in autoimmune diseases. Mol Immunol 2004;40:1095-102.

  34. 35.Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to β2-glycoprotein-Ia ccountsfortheinfectiousetiology of antiphospholipid syndrome. Journal of Clinical Investigation 2002;109(6):797-804.

  35. 36.Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001;124:1821-31.

  36. Gherardi RK, AuthierFJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus 2012;21:184-9.

  37. 38.Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P, Jara LJ, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol 2013;9(4):361-73.

  38. Lujan L, Perez M, Salazar E, et al . Autoimmune/autoinf lammator y syndrome induced by adjuvants (ASIA syndrome) in commercial sheep. Immunol Res 2013;56(2-3):317- 24.

  39. 40.Hoffmann MH, Tuncel J, Skriner K, et al. The Rheumatoid Arthritis-Associated Autoantigen hnRNP-A2 (RA33) Is a Major Stimulator of Autoimmunity in Rats with Pristane-Induced Arthritis. J Immunol 2007;179(11):7568-76.

  40. 41.Wester L, Olofsson P, Ibrahim SM., Holmdahl R. Chronicity of pristane-induced arthritis in rats is controlled by genes on chromosome 14. J Autoimmun 2003;21(4):305-13.

  41. 42.Holm BC, Lorentzen JC, Bucht A. Adjuvant oil induces waves of arthritogenic lymph node cells prior to ar thritis onset. Clin Exp Immunol 2004;137(1):59-64.

  42. 43.Ratkay LG, Zhang L, Tonzetich J, Waterfield JD. Complete Freund's Adjuvant Induces an Earlier and More Severe Arthritis in MRL-ipr Mice. J Immunol 1993;151:7.

  43. 44.Svelander L, Mussener A, Erlandsson-Harris H, Kleinau S. Polyclonal Thl cells transfer oil-induced arthritis. Immunology 1997;91:6.

  44. 45.Lorentzen JC, Glaser A, Jacobsson L, Galli J, Fakhrai-Rad H, Klareskog L, Luthman H. Identification of rat susceptibility loci for adjuvantoil- induced arthritis. Proc Natl Acad Sci USA 1998;95:5.

  45. 46.Kleinau S Erlandsson H, Klareskog L. Percutaneous exposure of adjuvant oil causes arthritis in DA rats. Clin Exp Immunol 1994;96:5.

  46. 47.Holm Bc Xu HW, Jacobsson L, Larsson A, Luthman H, Lorentzen JC. Rats made congenic for Oia3 on chromosome 10 become susceptible to squaleneinduced arthritis. Hum Mol Gen 2001;10(6):8.

  47. 48.Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The Endogenous Adjuvant Squalene Can Induce a Chronic T-Cell-Mediated Arthritis in Rats. Am J Pathol 2000;156:2057-65.

  48. 49.Satoh M, Reeves WH. Induction of Lupusassociated Autoantibodies in BALB/c Mice by Intraperitoneal Injection of Pristane. J Exp Med 1994;180:6.

  49. 50.Satoh M, Kumar A, Kanwar YS, Reeves WH. Antinuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA 1995;92:10934-8.

  50. 51.Feng D, Yang L, Bi X, Stone RC, Patel P, Barnes BJ. Protection of Irf5-deficient mice from pristaneinduced lupus involves altered cytokine production and class switching. Eur J Immunol 2012;42(6):1477- 87.

  51. 52.Richards HB, Satoh M, Jennette JC, Okano T, Kanwar YS, Reeves WH. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin Exp Immunol 1999;115:547-53.

  52. 53.Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. Interleukin 6 Dependence of Anti- DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristaneinduced Lupus. J Exp Med 1998;188(5):6.

  53. 54.Summers SA, Odobasic D, Khouri MB, Steinmentz OM, Yang Y, Holdsworth SR, Kitching AR. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane. Clin Exp Immunol 2014;176:342-50.

  54. 55.Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine Models of Systemic Lupus Erythematosus. J Biomed Biotechnol 2011;2011:1-19.

  55. 56.Alijotas-Reig J. Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria. Lupus 205;24:7.

  56. 57.Bagavant H, Nandula SR, Kaplonek P, Rybakowska PD, Deshmukh US. Alum, an aluminium based adjuvant, induces Sjogren's syndrome-like disorder in mice. Clin Exp Rheumatol 2014;32(2):251-5.

  57. 58.Kong YCM, Audibert F, Giraldo AA, Rose NR, Chedid L. Effects of Natural or Synthetic Microbial Adjuvant son Induction of Autoimme Thyroiditis. Infect Immun 1985:40-5.

  58. 59.Rose NR. The adjuvant effect in infection and autoimmunity. Clin Rev Allergy Immunol 2008;34(3):279-82.

  59. 60.Vladutiu AO, Rose NR. Autoimmune murine thyroiditis relation to histocompatibility (H-2) type. Science 1971;174(4014):1137-9.

  60. 61.Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M , ShoenfeldY. Induction of primary antiphospholipid syndrome in miceby imunizationwitha huanmn al anticardiolipin antibody (H-3). J Clin Invest 1992;89:1558-63.

  61. 62.Blank M, Israeli E, Shoenfeld Y. When APS ( Hughes syndromemet the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus 2012;21:711-4.

  62. 63.Inic-Kanada A, Stojanovic M, Sivkovic I, Kosec D, Micic M, Petrusic V, et al. Murine monoclonal antibody 26 raised against tetanus toxoid cross-reacts with b2-Glycoprotein I: Its characteristics and role in molecular mimicry. Am J Reprod Immunol 2009;61:39-51.

  63. 64.Živković I, Stojanović M, Petrušić V, Inić-Kanada A, Dimitrijević L. Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice. Am J Reprod Immunol 2011;65:492-502.

  64. 65.Dimitrijević L, ivković I, Stojanović M, Petrušić V, ivančević-Simonović S. Vaccine model of antiphospholipid syndrome induced by tetanus vaccine. Lupus 2012;21:195-202

  65. 66.Živkovič I, Petrušić V, Stojanović M, Inić-Kanada A, Stojićević I, Dimitrijevič L. Induction of decreased fecundity by tetanus toxoid hyperimmunization in C57BL/6 mice depends on the applied adjuvant. Innate Immunity 2011;18(2):333- 42. 67.Živkovič I, Petrušić V, Dimitrijevič R, Stojanović M, Dimitrijevič L. Adjuvant dependence of APS pathology-related low affinity antibodies during secondary immune response to tetanus toxoid in BALB/c mice. Immunol Res 2013;56:143-9.

  66. 68.Petrušić V, ivković I, Muhandes L, Dimitrijević R, Stojanović M, Dimitrijević L. Infection-induced autoantibodies and pregnancy related pathology: An animal model. Rep Fert Dev 2014;26:578-86.

  67. 69.Petrušić V, Todorovič, ivkovič I, Dimitrijevič R, Muhandes L, Rajnpreht I, et al. Autoantibody response and pregnancy-related pathology induced bycombined L P Sand tetanustoxoid hyperimmunization in BALB/c and C57BL/6 mic. Autoimmunity 2015;48(2):87-99.

  68. 70.Koppang EO, Bjerkas I, Haugarvoll E, et al. Vaccination-Induced Systemic Autoimmunity in Farmed Atlantic Salmon. J Immunol 2008;181(7):4807-14.

  69. White R.F, Steele L., O'Callaghan J.P., Sullivan K., Binns J.H., Golomb B.A., Bloom F.E., Bunker J.A, et al. Recent research on Gulf War illness and other health problems in veterans of the 1991 Gulf War: Effects of toxicant exposures during deployment. Cortex 2016;74:449-475.

  70. Israeli E. Gulf war syndrome as a part of the autoimmune (autoinf lammator y) syndrome induced by adjuvant (ASIA). Lupus 2012;21:190- 194.

  71. Stelle L, Lockridge O, Gerkovich MM, Cook MR, Sastre A. Butyrylcholinesterase genotype and enzyme activity in relation to Gulf War illness: preliminary evidence of gene-exposure interaction from a case-control study of 1991 Gulf War veterans. Environmental Health 2015;14:4.

  72. Steele L, Sastre A, Gerkovich MM, Cook MR. Complex factors in the etiology of Gulf War illness: wartime exposures and risk factors in veteran subgroups. Environmental Health Perspectives. 2012; 120(1):112–118.

  73. Kang HK, Mahan CM, Lee KY, Magee CA, Murphy FM. Illnesses among United States veterans of the Gulf War: a population-based survey of 30, 0 0 0 veterans. Jour nalof Occupational and Environmental Medicine. 2000; 42(5):491–501. 76. Haley RW, Marshall WW, McDonald GG, Daugherty MA, Petty F, Fleckenstein JL. Brain abnormalities in Gulf War syndrome: evaluation with 1H MR spectroscopy. Radiology. 2000; 215(3):807–817.

  74. Norbäck D. An update on sick building syndrome. Current Opinion in Allergy and Clinical Immunology. 2009;9:55-59.

  75. Thörn Ä. The sick building syndrome: a diagnostic dilemma. Soc Sci Med 1998; 47:1307–1312.

  76. Runeson R, Wahlstedt K, Wieslander G, Norba¨ck D. Personal and psychosocial factors and symptoms compatible with sick building syndrome in the Swedish workforce. Indoor Air 2006; 16:445–453.

  77. Bakke JV, Norba¨ck D, Wieslander G, et al. Symptoms, complaints, ocularandnas al physiological signs in university staff in relation to indoor environment–temperature and gender interactions. Indoor Air 2008; 18:131–143.

  78. Seppänen OA, Fisk WJ. Summary of human responses to ventilation. Indoor Air 2004; 14(7):102–118.

  79. Buchanan ISH, Mendell MJ, Mirer AG, Apte MG. Air filter materials, outdoor ozone and building related symptoms in the BASE study. Indoor Air 2008;18:144–155.

  80. Gherardi R.K., Coquet M., Cherin P., Authier F.J., Laforêt P., Belec L. et al. Macrophagic myofasciitis: an emerging entity. Lancet 1998;32:347-52.

  81. Authier F.J., Cherin P., Creange A., Bonnotte B., Ferrer X., Abdelmoumni A., et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001;124:974-983.

  82. Misbah S.A., Ozols B., Franks A., Mapstone N. Whipple´s disease without malabsortion: new atypical features. Q J Med 1997;17:516-24. 86. Cabral AR, Alcocer-Varela J, Orozco-Topete R, Reyes E, Fernández-Domínguez L, Alarcón- Segovia D. Clinical, histop athological, immunological and fibroblast studies in 30 patients with subcutaneous injections of modelants including silicone and mineral oils. Rev. Invest. Clin. 1994;46(4):257–266.

  83. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. AdJuvantsandautoimmunity. Lupus 2009;18(13):1217–1225.

  84. Cooper C, Dennison E. Do silicone breast implants cause connective tissue disease? BMJ 1998;316:403- 4.

  85. O 'Hanlon T, Koneru B, Bayat E et al . ; En vironmental Myositis Study Group . Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Ar thritis Rheum. 2004;50(11): 3646–3650.

  86. Janowsky E.C., Kupper L.L, Hulka B.S. Metaanalyses of the relation between silicone breast implants and the risk of connective-tissue diseases. New Eng J Med 2000;342:781-90.

  87. Hennekens CH, Lee I-M, Cook NR, et al. Selfreported breast implants and connective-tissue diseases in female health professionals: a retrospective cohort study. JAMA 1996;275:616-21.

  88. Lewin SL, Miller TA. A review of epidemiologic studies analyzing the relationship between breast implants and connective tissue diseases. Plast Reconstr Surg 1997;100:1309-13.

  89. Lasky, T., Terraciano, G., Magder, L., Koski, C., Ballesteros, M., Nash. D., Clark, S., Haber, P., Stolley, P., Schonberger, L., & Chen R. The guillain–barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 2002;346(24):1845–53.

  90. De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher R-M, et al. Risk of Guillain- Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA. 2012;308(2):175–81

  91. Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.

  92. Maeda K, Idehara R. Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccination. Internal medicine (Tokyo, Japan). 2012. p. 1931–3.

  93. 97.Agmon-Levin N, Zafrir Y, Paz Z, Shilton T, Zandman-Goddard G, Shoenfeld Y. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus. 2009;18(13):1192–7.

  94. Stübgen JP. A review on the association between inflammator y myopathies and vaccination. Autoimmunity Reviews. 2014. p. 31–9.

  95. Colafrancesco S, Perricone C, Priori R, Valesini G, Shoenfeld Y. Sj??gren's syndrome: Another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). J Autoimmun. 2014. p. 10–6.

  96. Hawkes D, Benhamu J, Sidwell T, Miles R, Dunlop RA. Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA). J Autoimmun. 2015;59:77–84.

  97. Dagan A, Kogan M, Shoenfeld Y, Segal G. When uncommon and common coalesce: adult onset Still's disease associated with breast augmentation as part of autoimmune syndrome induced by adjuvants (ASIA). Clin Rheumatol. 2015;

  98. Stejskal V. Metals as a common trigger of inflammation resulting in non-specific symptoms: Diagnosis and treatment. Isr Med Assoc J. 2014;16(12):753–8.

  99. Cohen Tervaert JW, Kappel RM. Silicone implant incompatibility syndrome (SIIS): A frequent cause of ASIA (Shoenfeld's syndrome). Immunol Res. 2013;56(2-3):293–8.

  100. Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: Who might be at risk? Pharmacol Res. 2015;92:18–22.




2020     |     www.medigraphic.com